Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Clene ( (CLNN) ) has shared an announcement.
On April 28, 2025, Clene Inc. entered into an equity distribution agreement with Canaccord Genuity LLC to offer and sell shares of its common stock, aiming to raise up to $25 million. By July 3, 2025, Clene had filed a prospectus supplement for an additional $2,015,000 in shares, indicating ongoing efforts to secure funding for its operations and potentially strengthen its market position.
The most recent analyst rating on (CLNN) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Clene stock, see the CLNN Stock Forecast page.
Spark’s Take on CLNN Stock
According to Spark, TipRanks’ AI Analyst, CLNN is a Neutral.
Clene’s overall score is driven by significant financial challenges, including declining revenues and high net losses. However, positive regulatory updates and improved technical indicators provide some support. Valuation remains a concern due to the negative P/E ratio.
To see Spark’s full report on CLNN stock, click here.
More about Clene
Clene Inc. operates in the biotechnology industry, focusing on the development of innovative therapies for neurodegenerative diseases. The company is engaged in advancing its proprietary technology to address unmet medical needs in this market.
Average Trading Volume: 92,684
Technical Sentiment Signal: Sell
Current Market Cap: $35.03M
For a thorough assessment of CLNN stock, go to TipRanks’ Stock Analysis page.